Medtronic plc (MDT)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns and sell at a sensible price. Medtronic is a large, established medical-device company with a broad portfolio spanning cardiovascular, neuroscience, and medical surgical products. In fiscal Q1 2027, the quarter ended 2026-07-31, revenue was $9.8B, net income $1.5B, and diluted EPS $1.14, compared with $8.6B, $1.0B, and $0.81 in fiscal Q1 2026, the quarter ended 2025-07-25. For FY2026, the fiscal year ended 2026-04-24, filed revenue was $36.4B, net income $4.8B, and diluted EPS $3.73, versus $33.5B, $4.7B, and $3.61 in FY2025, the fiscal year ended 2025-04-25. That is respectable, but FairStock’s Lynch category is SLOW GROWER, based on 5.9% annual profit growth and 3.8% revenue growth over five years. The moat is suggested by scale and a diversified device portfolio, but the slow five-year record shows it has not produced high growth. Financial health looks adequate: debt/equity is 0.55, free cash flow is $6.1B, and the FCF yield is 5.1%. But FairStock’s computed ROE is 10.65% and ROCE is 5.12%, not high by my standards. At the 2026-10-26 close of $94.79, FairStock shows P/E 23.35, P/B 2.42, Graham Number $59.87, and margin of safety -59.36%, so the price is not a Graham bargain. The 3.13% dividend yield and beta 0.57 add defensiveness. I would call it a fair business at a full-to-fair price, needing better returns and growth to earn enthusiasm.

In plain English: Medtronic makes medical devices and therapies used in heart care, brain and spine care, and surgery. The business is profitable and produces cash, but its long-term growth has been slow. At $94.79 on 2026-10-26, the shares look fair to slightly expensive compared with earnings and book value, not a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-07-31) · fiscal Q3 2026 10-Q (period ended 2026-01-23) · fiscal Q2 2026 10-Q (period ended 2025-10-24) · fiscal Q1 2026 10-Q (period ended 2025-07-25) · FY2026 10-K (period ended 2026-04-24) · FY2025 10-K (period ended 2025-04-25) · FY2024 10-K (period ended 2024-04-26)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer